Africa Needs Urgent Action To Protect ‘Miracle’ Malaria Drugs 

The Looming Crisis of Antimalarial Drug Resistance

For years, Artemisinin-based combination therapy (ACT) has been the gold standard for treating malaria across Africa. As the primary first-line treatment recommended by the World Health Organization (WHO), ACT has saved millions of lives. However, a dangerous trend is emerging: the parasites are evolving.

We are seeing a rise in partial resistance, where parasites become resistant to artemisinin, one of the two drugs typically used in the combination. This phenomenon has already been confirmed in Rwanda, Uganda, Eritrea, and Tanzania, with suspicions of spread in at least four other countries.

From Detection to Action: The “Orange to Red” Warning

Experts warn that the world is currently in a precarious transition. Professor Deus Ishengoma describes a progression of resistance that moves from “orange to red.” Although we are seeing signs of patients not curing as expected, the “red” stage represents full treatment failure.

The danger is that many countries stop at detection. Data is collected, but the financing and coordination required to pivot to new treatments are often missing. If the region hits the fourth stage of resistance, the result is “panic mode” and a significant jump in mortality.

Diversifying the Arsenal: Beyond Artemisinin

To prevent a total collapse of malaria treatment, the strategy is shifting toward drug diversification. By utilizing multiple different drugs, it becomes significantly harder for parasites to acquire resistance to every available option as they move from person to person.

Currently, there are four ACTs realistically available for leverage in Africa, though challenges remain regarding cost, and scalability. The future of malaria treatment lies in the pipeline of new medicines, including promising options that do not rely on artemisinin at all.

The Role of Next-Generation Tools

While new drugs are developed, a multi-layered approach is essential. This includes:

• Vaccines: Providing a new layer of biological protection.
• Chemoprevention: Administering preventative drug courses to the most vulnerable populations.
• Insecticide-Treated Nets: The first line of physical defense.

However, the challenge is compounding. Not only are the parasites becoming resistant to drugs, but some mosquitoes are becoming resistant to the insecticides used on bed nets, reducing their overall effectiveness.

The Economic and Human Cost of Delay

The cost of waiting for drugs to fail completely is catastrophic. Mathematical modelling by Oliver Watson from Imperial College London suggests that delaying action could lead to up to half a billion additional patients who cannot be cleared of infection.

This isn’t just a health crisis; It’s an economic one. Patients struggling with malaria cannot work or feed their families, leading to massive economic losses. The additional pressure on households and health systems could plausibly exceed one billion dollars over the next 15 years.

Real-world examples highlight the vulnerability of these systems. In Kano, Nigeria, residents like Hassana Sa-adu rely entirely on government-provided free nets. When nets become ancient and full of holes, families remain exposed, and children frequently fall sick with fever, demonstrating the fragile nature of prevention in high-burden areas.

Case Study: Proactive Procurement in Burkina Faso

Not all responses are delayed. Professor Maciej Boni highlights Burkina Faso as a positive example. The country took the initiative to procure alternative drugs before artemisinin resistance was even detected within its borders. This proactive approach serves as a model for other East and West African nations to avoid the “red zone” of treatment failure.

Strengthening the First Line of Defense

The battle against malaria is far from lost, but it requires a shift in funding and leadership. With the decrease in funding from sources like USAID, the burden of innovation and implementation is shifting. There is a growing call for African nations to lead their own solutions and secure international funding to implement drug alternatives within 6 to 12 months in affected areas.

Progress is possible. In 2025, Georgia, Suriname, and Timor-Leste were declared malaria-free, proving that eradication is achievable with the right tools and political will.